Patritumab deruxtecan (HER3-DXd) in early-stage HR+/HER2-breast cancer: Final results of the SOLTI TOT-HER3 window of opportunity trial-MedSci.cn

Patritumab deruxtecan (HER3-DXd) in early-stage HR+/HER2-breast cancer: Final results of the SOLTI TOT-HER3 window of opportunity trial

Prat, A; Falato, C; Brunet, LP; Saez, OM; Andujar, JMC; Vila, MM; Tolosa, P; Bofill, FJS; Jurado, JC; Gonzalez-Farre, B; Torres, ES; Ciruelos, EM; Espinosa-Bravo, M; Peron, YI; Simon, SP; Esker, S; Fan, PD; Cafiero, JMF; Pascual, T; Oliveira, M

ANNALS OF ONCOLOGY, 2022; 33 (): S164

科室
- - 订阅+
  - 更多科室
工具
服务